Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

157.79
+1.030.66%
Post-market: 159.932.14+1.36%17:36 EDT
Volume:1.04M
Turnover:163.13M
Market Cap:16.09B
PE:23.13
High:160.43
Open:157.39
Low:155.09
Close:156.76
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.98
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.36
PE(LYR):33.79

Loading ...

Centene, Deckers and 14 Other 'Dividend Hopefuls' -- Barrons.com

Dow Jones
·
Jun 02

Neurocrine Biosciences CSO Jude Onyia sells 11,000 shares for $1.71 million

Reuters
·
May 30

Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says

MT Newswires Live
·
May 30

RBC Lifts Price Target on Neurocrine Biosciences to $183 From $180, Keeps Outperform Rating

MT Newswires Live
·
May 29

Neurocrine Chief Corporate Affairs Officer David W. Boyer disposes of 3,888 shares worth $609,019.12

Reuters
·
May 29

Neurocrine Biosciences shareholders approved amended 2025 equity incentive plan at annual meeting

Reuters
·
May 29

Beyond Next Ventures leads SCOHIA PHARMA private funding round raising JPY 3 billion

Reuters
·
May 28

New Real‑World INGREZZA Data in Mild TD Might Change The Case For Investing In Neurocrine Biosciences (NBIX)

Simply Wall St.
·
May 27

Neurocrine executives to speak at William Blair growth stock conference

Reuters
·
May 27

Neurocrine Initiated at Outperform by Bernstein

Dow Jones
·
May 22

Bernstein Initiates Coverage on Neurocrine Biosciences With Outperform Rating

MT Newswires Live
·
May 22

Neurocrine director Kevin Charles Gorman disposes 245,088 shares for $37.82 million

Reuters
·
May 22

Neurocrine initiated with Outperform at Bernstein on long runway of key drugs

TIPRANKS
·
May 22

Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention

Simply Wall St.
·
May 21

New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX)

Simply Wall St.
·
May 20

Bausch Health elects Eiry Roberts to board, names her science and technology chair

Reuters
·
May 20

Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors

TIPRANKS
·
May 20

VistaGen appoints Angel Angelov as chief medical officer

Reuters
·
May 19

Neurocrine director Richard F. Pops disposes 15,000 shares worth $2.36 million

Reuters
·
May 19

Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules

MT Newswires Live
·
May 19